By vgreene, 2 March, 2020 Exclude Patient Type Detail Header No Detail Type Text Detail Text TDF/FTC (Truvada) 300 mg/200 mg daily,4 ≤90-day supply [IA] F/U q3mo for HIV test [IA],5 med adherence counseling, risk redux support [IIIA], ADR & STI assessment; test (incl oral + rectal) for bacterial STIs (syphilis, gonorrhea, chlamydia) q3mo if high risk for recurrent STI (recent STI or multiple partners) Vaccinate pts determined to be susceptible to HBV infxn2 Perform HCV testing as part of baseline lab eval; consider annual retesting for those w/ ongoing risk of HCV exposure Counsel pts on how to safely d/c and restart PrEP both when starting PrEP and when d/c’ing PrEP as HIV infxn protection wanes 7-10 days after ceasing daily PrEP use Patient Type Detail Header (Long) Adult MSM/bisexual males who inject drugs<sup>3</sup>